Published in J Natl Cancer Inst on April 07, 1993
Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer (1999) 1.71
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
Astrocytes directly influence tumor cell invasion and metastasis in vivo. PLoS One (2013) 1.56
Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer (1998) 1.53
Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J (1998) 1.48
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer (2010) 1.48
Matrix metalloproteinase inhibitors. Invest New Drugs (1997) 1.43
Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol (2008) 1.41
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther (2005) 1.33
MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis (2000) 1.26
Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A (1996) 1.11
A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer (2001) 1.08
Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer (1995) 1.07
Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs (1997) 0.99
A biological staging model for operable non-small cell lung cancer. Thorax (2001) 0.95
Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer (2001) 0.92
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 0.90
Surrogate markers in antiangiogenesis clinical trials. Br J Cancer (2003) 0.90
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer (2003) 0.89
Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis. J Clin Pathol (1999) 0.88
Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer (1996) 0.88
KAI1 is a potential target for anti-metastasis in pancreatic cancer cells. World J Gastroenterol (2008) 0.88
Effects of RNAi-mediated matrix metalloproteinase-2 gene silencing on the invasiveness and adhesion of esophageal carcinoma cells, KYSE150. Dig Dis Sci (2011) 0.86
Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor. Clin Exp Metastasis (2000) 0.86
Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int J Colorectal Dis (2007) 0.85
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs (2002) 0.84
Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells. Br J Cancer (1996) 0.84
Detection of matrix metalloproteinase activity in human pancreatic cancer. Surg Today (1997) 0.84
Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer. Br J Cancer (1998) 0.84
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs (1997) 0.82
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src. Clin Exp Metastasis (1999) 0.81
Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer. J Cardiothorac Surg (2015) 0.81
Gynura procumbens ethanolic extract suppresses osteosarcoma cell proliferation and metastasis in vitro. Oncol Lett (2013) 0.81
Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer. BMC Clin Pathol (2012) 0.81
Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers. Br J Clin Pharmacol (2006) 0.80
Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis (1997) 0.79
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. Br J Cancer (1996) 0.79
Genetic background of adrenocortical tumor development. World J Surg (2001) 0.78
Chlorotoxin-Fc fusion inhibits release of MMP-2 from pancreatic cancer cells. Biomed Res Int (2014) 0.78
Comparative expression of matrix metalloproteinases in low-grade mucoepidermoid carcinoma and typical lung cancer. Oncol Lett (2011) 0.78
Role of proteases in pancreatic carcinoma. World J Surg (2005) 0.77
Catalyser-21(TM), a mineral water derived from leaf soil, inhibits tumor cell invasion and angiogenesis. Cytotechnology (2007) 0.75
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol (1994) 5.34
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol (1990) 4.42
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med (1993) 4.05
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med (1983) 3.63
Ki67 protein: the immaculate deception? Histopathology (2002) 3.61
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
The Bloom's syndrome gene product interacts with topoisomerase III. J Biol Chem (2000) 3.52
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
Transferrin receptor on endothelium of brain capillaries. Nature (1984) 3.37
Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol (1983) 3.23
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol (1990) 3.10
Monoclonal antibody Ki-67: its use in histopathology. Histopathology (1990) 3.07
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci U S A (1991) 2.82
KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol (1989) 2.82
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J Clin Pathol (1982) 2.69
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Immunohistological analysis of human mononuclear phagocytes and dendritic cells by using monoclonal antibodies. Lab Invest (1986) 2.42
Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood (1990) 2.40
Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques. Lancet (1985) 2.40
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30
Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet (1990) 2.25
Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet (1984) 2.25
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst (1993) 2.22
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Association between platelet microthrombi and finger clubbing. Lancet (1991) 2.20
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol (1998) 2.05
Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature (1992) 2.03
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A (2000) 1.88
Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation. Lancet (1990) 1.86
Detection of T cells in paraffin wax embedded tissue using antibodies against a peptide sequence from the CD3 antigen. J Clin Pathol (1989) 1.85
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet (2001) 1.81
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81
Cytokeratin expression in smooth muscle and smooth muscle tumours. Histopathology (1987) 1.78
The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer (1984) 1.77
Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer (1985) 1.76
Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) (1981) 1.75
A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol (1995) 1.67
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer (2002) 1.62
Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems? Med Care (2001) 1.61
The role of immunocytochemistry in diagnostic pathology. J Clin Pathol (1987) 1.59
Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res (1993) 1.58
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57
Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer (2001) 1.56
An immunohistological study of the cellular constituents of Hodgkin's disease using a monoclonal antibody panel. Histopathology (1984) 1.55
Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. Br J Dis Chest (1982) 1.55
Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A (1995) 1.54
Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect Immun (1994) 1.51
The utility of Ki67 immunostaining, nuclear organizer region counting, and morphology in the assessment of follicular lymphomas. J Pathol (1989) 1.50
New approach to assessing lung tumours in man. J Clin Pathol (1986) 1.50
Barriers to following dietary recommendations in Type 2 diabetes. Diabet Med (2005) 1.49
Ways of escape: are all tumours angiogenic? Histopathology (2001) 1.48
Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol (1992) 1.48
The bone marrow trephine biopsy: a review of normal histology. Histopathology (1993) 1.48
Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol (2003) 1.47
Rearrangement of the T-cell-receptor beta-chain gene in the diagnosis of lymphoproliferative disorders. Lancet (1985) 1.46
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res (2001) 1.46
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol (1995) 1.45
Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol (1996) 1.42
Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma. Br Med J (1979) 1.41
Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. J Clin Pathol (1987) 1.41
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol (1998) 1.41
Monoclonal antibody (Y1/82A) with specificity towards peripheral blood monocytes and tissue macrophages. J Clin Pathol (1988) 1.41
Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res (2001) 1.41
Human lung tumours may coexpress different classes of intermediate filaments. J Clin Pathol (1986) 1.40
Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med (1985) 1.39
Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer (1998) 1.37
Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res (2001) 1.36
Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res (1987) 1.34
The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer (1996) 1.33
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2000) 1.33
Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int J Radiat Oncol Biol Phys (2001) 1.32
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 1.31
An immunohistological study of giant-cell tumour of bone: evidence for an osteoclast origin of the giant cells. J Pathol (1985) 1.31
Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia. Br J Cancer (2010) 1.30
Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene (1993) 1.30
Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest (2007) 1.26
The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br J Cancer (2004) 1.26
Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen. J Clin Pathol (1989) 1.26
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer (1997) 1.25
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res (2000) 1.25
Langerhans' cells in human cervical epithelium: an immunohistological study. Br J Obstet Gynaecol (1983) 1.25
Granular cell tumours revisited. An immunohistological and ultrastructural study. Histopathology (1988) 1.24
Immunophenotyping of non-Hodgkin's lymphomas using a panel of antibodies on paraffin-embedded tissues. Am J Pathol (1987) 1.23
Ki-67 immunostaining and survival in operable lung cancer. Histopathology (1991) 1.22